IMBiotechnologies Ltd (IMB) is a privately held Canadian biotechnology company whose focus is commercializing medical device products in the area of embolotherapy. Embolic agents target the treatment of benign and malignant growths (tumors). IMB is located in Edmonton, Alberta, with strategic proximity to centres of scientific and clinical excellence in interventional radiology.
IMB’s Lead Product Candidate, Occlusin® 500, is a “first in class” biodegradable embolic agent for the treatment of malignant and non-malignant vascularised tumors. Examples of vascularised tumors include heptocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids. Occlusin® 500 is also being developed to treat enlarged prostates due to benign prostatic hypertrophy/hyperplasia (BPH).
For more information, please contact us by calling: (780) 945-6609 or send us an email.